Fingerprint
Dive into the research topics of 'FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically